From target discovery to clinical drug development with human genetics

[1]  I. Dunham,et al.  Why Clinical Trials Stop: The Role of Genetics , 2023, medRxiv.

[2]  Kevin Y. H. Liang,et al.  Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity , 2023, Nature Metabolism.

[3]  Jacob C. Ulirsch,et al.  FinnGen provides genetic insights from a well-phenotyped isolated population , 2023, Nature.

[4]  P. Visscher,et al.  15 years of GWAS discovery: Realizing the promise. , 2023, American journal of human genetics.

[5]  Konstantinos D. Tsirigos,et al.  The next-generation Open Targets Platform: reimagined, redesigned, rebuilt , 2022, Nucleic Acids Res..

[6]  M. Fielden,et al.  Using human genetics to improve safety assessment of therapeutics , 2022, Nature Reviews Drug Discovery.

[7]  The Genomes-Project-Pilot-Investigators.  100,000 genomes pilot on rare-disease diagnosis in health care – preliminary report , 2022, Yearbook of Paediatric Endocrinology.

[8]  E. McDonagh,et al.  Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs , 2022, Nature Reviews Drug Discovery.

[9]  A. Philippakis,et al.  The potential of polygenic scores to improve cost and efficiency of clinical trials , 2022, Nature Communications.

[10]  R. Levine,et al.  Targeting mutations in cancer , 2022, The Journal of clinical investigation.

[11]  Eurie L. Hong,et al.  Whole-genome sequencing reveals host factors underlying critical COVID-19 , 2022, Nature.

[12]  K. C. Morris,et al.  Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis , 2022, medRxiv.

[13]  J. Witztum,et al.  THE EFFECT OF LONG-TERM USE OF ASPIRIN ON THE OUTCOMES OF COVID-19 INFECTION IN PATIENTS WITH A HISTORY OF CORONARY ARTERY DISEASE AND CHRONIC KIDNEY DISEASE , 2022, Journal of the American College of Cardiology.

[14]  Alicia R. Martin,et al.  Diversity in Genomic Studies: A Roadmap to Address the Imbalance , 2022, Nature Medicine.

[15]  Saptarsi M. Haldar,et al.  Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a) , 2022, Nature Medicine.

[16]  M. Irving,et al.  Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies , 2022, Therapeutic advances in musculoskeletal disease.

[17]  Bjarni V. Halldórsson,et al.  Large-scale integration of the plasma proteome with genetics and disease , 2021, Nature Genetics.

[18]  P. Scheltens,et al.  The Alzheimer’s disease drug development landscape , 2021, Alzheimer's Research & Therapy.

[19]  I. Dokal.  Faculty Opinions recommendation of 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[20]  M. Koschinsky,et al.  Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. , 2021, Arteriosclerosis, thrombosis, and vascular biology.

[21]  A. Janež,et al.  Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia , 2021, Expert opinion on drug safety.

[22]  M. Rivas,et al.  A cross-population atlas of genetic associations for 220 human phenotypes , 2021, Nature Genetics.

[23]  Mattia G. Bergomi,et al.  Mapping the human genetic architecture of COVID-19 , 2021, Nature.

[24]  R. Collins,et al.  Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity , 2021, Science.

[25]  Katie Kingwell.  Double setback for ASO trials in Huntington disease , 2021, Nature Reviews Drug Discovery.

[26]  A. Montpetit,et al.  The Biobanque québécoise de la COVID-19 (BQC19)—A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories , 2021, PloS one.

[27]  M. Krawczak,et al.  Balancing scientific interests and the rights of participants in designing a recall by genotype study , 2021, European Journal of Human Genetics.

[28]  Nicole M. Gaudelli,et al.  In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates , 2021, Nature.

[29]  Philip S. Insel,et al.  Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging , 2021, Alzheimer's Research & Therapy.

[30]  Margherita Francescatto,et al.  Natural human knockouts and Mendelian disorders: deep phenotyping in Italian isolates , 2021, European Journal of Human Genetics.

[31]  Asher Mullard.  FDA approves first anti-ANGPTL3 antibody, for rare cardiovascular indication , 2021, Nature Reviews Drug Discovery.

[32]  C. Greenwood,et al.  A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity , 2021, Nature Medicine.

[33]  Adriana I. Iglesias,et al.  Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries , 2021, Nature Communications.

[34]  Claude C. Warzecha,et al.  Long-term Stable Reduction of Low-density Lipoprotein in Nonhuman Primates Following In Vivo Genome Editing of PCSK9. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  Daniel F. Freitag,et al.  Mendelian randomization for studying the effects of perturbing drug targets , 2021, Wellcome open research.

[36]  A. Wonkam.  Sequence three million genomes across Africa , 2021, Nature.

[37]  J. Richards,et al.  A Polygenic Risk Score for Low-density Lipoprotein Cholesterol is Associated with Risk of Ischemic Heart Disease and Enriches for Individuals with Familial Hypercholesterolemia. , 2021, Circulation. Genomic and precision medicine.

[38]  David A. Williams,et al.  Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. , 2020, The New England journal of medicine.

[39]  C. Greenwood,et al.  Individuals with common diseases but with a low polygenic risk score could be prioritized for rare variant screening , 2020, Genetics in Medicine.

[40]  Anisah W. Ghoorah,et al.  High-depth African genomes inform human migration and health , 2020, Nature.

[41]  A. Telenti,et al.  Advances in Genomics for Drug Development , 2020, Genes.

[42]  Andrew J Chetwynd,et al.  Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype , 2020, Metabolomics.

[43]  M. Mckee,et al.  Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. , 2020, JAMA.

[44]  Spotlight on cancer genomics , 2020, Nature Cancer.

[45]  Matthew J. Daniels,et al.  Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations , 2020, American journal of physiology. Heart and circulatory physiology.

[46]  J. F. Staples,et al.  Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy , 2020, Circulation.

[47]  L. Siu,et al.  Molecular profiling for precision cancer therapies , 2020, Genome Medicine.

[48]  Min Wu,et al.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects , 2020, Signal Transduction and Targeted Therapy.

[49]  J. Tardif,et al.  Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. , 2020, The New England journal of medicine.

[50]  M. Rots,et al.  The timeline of epigenetic drug discovery: from reality to dreams , 2019, Clinical Epigenetics.

[51]  G. Abecasis,et al.  Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial , 2019, Circulation.

[52]  P. Ellinor,et al.  Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score , 2019, Circulation.

[53]  Jinkuk Kim,et al.  Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. , 2019, The New England journal of medicine.

[54]  Daniel F. Freitag,et al.  Genetic drug target validation using Mendelian randomisation , 2019, Nature Communications.

[55]  A. Olry,et al.  Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database , 2019, European Journal of Human Genetics.

[56]  Stephanie A. Bien,et al.  The Future of Genomic Studies Must Be Globally Representative: Perspectives from PAGE. , 2019, Annual review of genomics and human genetics.

[57]  V. Lauschke,et al.  Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe , 2019, European Journal of Human Genetics.

[58]  Ira M. Hall,et al.  Exome sequencing of Finnish isolates enhances rare-variant association power , 2019, Nature.

[59]  L. Cardon,et al.  Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study , 2019, Scientific Reports.

[60]  M. Rivas,et al.  Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma , 2019, bioRxiv.

[61]  E. Zeggini,et al.  Genomics of disease risk in globally diverse populations , 2019, Nature Reviews Genetics.

[62]  Mark R. Hurle,et al.  Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases , 2019, bioRxiv.

[63]  Alicia R. Martin,et al.  Clinical use of current polygenic risk scores may exacerbate health disparities , 2019, Nature Genetics.

[64]  Scott M. Williams,et al.  The Missing Diversity in Human Genetic Studies , 2019, Cell.

[65]  Ryan L. Collins,et al.  Evaluating drug targets through human loss-of-function genetic variation , 2019, Nature.

[66]  Mohan Liu.  F1000Prime recommendation of Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. , 2019, F1000 - Post-publication peer review of the biomedical literature.

[67]  Jacob F. Degner,et al.  Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval , 2019, bioRxiv.

[68]  R. Mägi,et al.  Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia , 2018, Genetics in Medicine.

[69]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[70]  Jamie R. Robinson,et al.  Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome , 2018, Clinical pharmacology and therapeutics.

[71]  C. von Kalle,et al.  Gene Therapy in Patients with Transfusion‐Dependent β‐Thalassemia , 2018, The New England journal of medicine.

[72]  C. Turnbull,et al.  Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes Project. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  Alexander E. Lopez,et al.  A Protein‐Truncating HSD17B13 Variant and Protection from Chronic Liver Disease , 2018, The New England journal of medicine.

[74]  V. Mooser,et al.  High participation rate among 25 721 patients with broad age range in a hospital-based research project involving whole-genome sequencing - the Lausanne Institutional Biobank. , 2017, Swiss medical weekly.

[75]  D. Lawlor,et al.  Assessing the Causal Role of Body Mass Index on Cardiovascular Health in Young Adults , 2017, bioRxiv.

[76]  Daniel G. MacArthur,et al.  Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity , 2017, Nature.

[77]  Y. Kamatani,et al.  Overview of the BioBank Japan Project: Study design and profile , 2017, Journal of epidemiology.

[78]  P. Sankar,et al.  The Precision Medicine Initiative’s All of Us Research Program: an agenda for research on its ethical, legal, and social issues , 2016, Genetics in Medicine.

[79]  Tudor I. Oprea,et al.  A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.

[80]  R. Harrison,et al.  Phase II and phase III failures: 2013–2015 , 2016, Nature Reviews Drug Discovery.

[81]  S. Fullerton,et al.  Genomics is failing on diversity , 2016, Nature.

[82]  D. Russell,et al.  Steroid 5α-reductase 2 deficiency , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[83]  V. Mooser,et al.  Identification and molecular characterisation of Lausanne Institutional Biobank participants with familial hypercholesterolaemia - a proof-of-concept study. , 2016, Swiss medical weekly.

[84]  Clint L. Miller,et al.  Integrative functional genomics identifies regulatory mechanisms at coronary artery disease loci , 2016, Nature Communications.

[85]  A. Bailey.  Acknowledgements , 2016, Biological Psychiatry.

[86]  J. Collinge,et al.  Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. , 2016, JAMA neurology.

[87]  Lisa A. Raedler.  Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia. , 2016, American health & drug benefits.

[88]  Tom R. Gaunt,et al.  Importance of Genetic Studies in Consanguineous Populations for the Characterization of Novel Human Gene Functions , 2016, Annals of human genetics.

[89]  E. Zeggini,et al.  Integrative epigenomics, transcriptomics and proteomics of patient chondrocytes reveal genes and pathways involved in osteoarthritis , 2016, Scientific Reports.

[90]  N. Seidah.  The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol , 2015, Global cardiology science & practice.

[91]  B. Ference.  Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps , 2015, Current opinion in lipidology.

[92]  Nicholas J. Timpson,et al.  Genetics, sleep and memory: a recall-by-genotype study of ZNF804A variants and sleep neurophysiology , 2015, BMC Medical Genetics.

[93]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[94]  Judy H. Cho,et al.  Expanded genetic screening panel for the Ashkenazi Jewish population , 2015, Genetics in Medicine.

[95]  Vivien Marx,et al.  The DNA of a nation , 2015, Nature.

[96]  R. Mägi,et al.  Cohort Profile Cohort Profile : Estonian Biobank of the Estonian Genome Center , University of Tartu , 2015 .

[97]  Jeffery L. Painter,et al.  The support of human genetic evidence for approved drug indications , 2015, Nature Genetics.

[98]  Joshua C. Denny,et al.  TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits , 2015, PloS one.

[99]  Bjarni V. Halldórsson,et al.  Large-scale whole-genome sequencing of the Icelandic population , 2015, Nature Genetics.

[100]  L Zhang,et al.  Racial/ethnic differences in drug disposition and response: Review of recently approved drugs , 2015, Clinical pharmacology and therapeutics.

[101]  Vincent Mooser,et al.  The Lausanne Institutional Biobank: a new resource to catalyse research in personalised medicine and pharmaceutical sciences. , 2014, Swiss medical weekly.

[102]  G. Davey Smith,et al.  Mendelian randomization: genetic anchors for causal inference in epidemiological studies , 2014, Human molecular genetics.

[103]  Faisal M. Fadlelmola,et al.  Enabling Genomic Revolution in Africa , 2019, The Genetics of African Populations in Health and Disease.

[104]  M. McCarthy,et al.  Research Capacity: Enabling African Scientists to Engage Fully in the Genomic Revolution , 2014 .

[105]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[106]  J. Arrowsmith,et al.  Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.

[107]  S. S. Hall.  Genetics: A gene of rare effect , 2013, Nature.

[108]  R. Desnick,et al.  Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. , 2012, Annual review of genomics and human genetics.

[109]  F. Blanco-Vaca,et al.  Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[110]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[111]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[112]  D. Labuda,et al.  Admixed ancestry and stratification of Quebec regional populations. , 2011, American journal of physical anthropology.

[113]  Jonathan C. Cohen,et al.  Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. , 2010, The New England journal of medicine.

[114]  D. Adriaensen,et al.  First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function , 2010, Human mutation.

[115]  P. Negulescu,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[116]  Eric Boerwinkle,et al.  Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. , 2008, The Journal of clinical investigation.

[117]  Luigi Ferrucci,et al.  Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. , 2008, American journal of human genetics.

[118]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[119]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[120]  Jonathan C. Cohen,et al.  Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. , 2006, American journal of human genetics.

[121]  Marie-Pierre Dubé,et al.  Human monogenic disorders — a source of novel drug targets , 2006, Nature Reviews Genetics.

[122]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[123]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[124]  B. Brais,et al.  Population history and its impact on medical genetics in Quebec , 2005, Clinical genetics.

[125]  M. Slatkin.  A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases. , 2004, American journal of human genetics.

[126]  Sarah A Tishkoff,et al.  Patterns of human genetic diversity: implications for human evolutionary history and disease. , 2003, Annual review of genomics and human genetics.

[127]  Bhushan Kumar,et al.  Minoxidil vs finasteride in the treatment of men with androgenetic alopecia. , 2003, Archives of dermatology.

[128]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[129]  K. Lindpaintner,et al.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease , 2002, Journal of medical genetics.

[130]  R C Bruskewitz,et al.  The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. , 2002, The New England journal of medicine.

[131]  F. Collins,et al.  Shattuck lecture--medical and societal consequences of the Human Genome Project. , 1999, The New England journal of medicine.

[132]  J. Shapiro,et al.  Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. , 1998, Journal of the American Academy of Dermatology.

[133]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[134]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[135]  J. Weissenbach,et al.  An international two–stage genome–wide search for schizophrenia susceptibility genes , 1995, Nature Genetics.

[136]  A. Chapelle,et al.  Disease gene mapping in isolated human populations: the example of Finland. , 1993, Journal of medical genetics.

[137]  G. Andriole,et al.  The effect of finasteride in men with benign prostatic hyperplasia. , 1992, The Journal of urology.

[138]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[139]  Daniel F. Freitag,et al.  Mendelian randomization for studying the effects of perturbing drug targets. , 2021, Wellcome open research.

[140]  J. Davies,et al.  Gene Therapy in a Patient with Sickle Cell Disease. , 2017, The New England journal of medicine.

[141]  Guidance for Industry Clinical Pharmacogenomics : Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling , 2013 .

[142]  H. Watkins,et al.  Inherited cardiomyopathies. , 2011, The New England journal of medicine.

[143]  FDA approves maraviroc tablets. , 2007, AIDS patient care and STDs.

[144]  P. Donnelly,et al.  Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. , 2007, Nature genetics.

[145]  T. Ma,et al.  Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. , 2003, The Journal of biological chemistry.

[146]  Antiviral Briefs. , 2002, AIDS patient care and STDs.

[147]  International Human Genome Sequencing Consortium.  Initial sequencing and analysis of the human genome , 2001, Nature.

[148]  H. Mabuchi,et al.  Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. , 1981, The New England journal of medicine.